Denosumab biosimilar (Biocon)

Mumbai: Zydus Lifesciences has announced the launch of its Denosumab biosimilar brand ‘ Zyrifa ’ in India. Zyrifa , a biosimilar of Amgen ’s blockbuster brand Xgeva (Denosumab) is approved for prevention of skeletal complications in cancer patients. “With Denosumab 120 mg SC, we aim to bring access, affordability of medication in cancer patients needing critical care. This will help patients to retain mobility, and support them in their fight against cancer,” said Dr Sharvil Patel, MD, Zydus Lifesciences Limited. The Ahmedabad-based drugmaker has priced its brand at Rs 12,495, and the company is expected to subsequently launch a generic version of Prolia, indicated for osteoporosis. Zydus has yet to disclose its Prolia strategy, and requests for clarification from ETPharma remained unanswered. Besides, Zydus several Indian drugmakers including Dr Reddy’s, Aurobindo are also working on their respective biosimilar brands, however the market entry plans are yet to be disclose Meanwhile, another drugmaker, Biocon, is marketing Vevzuo and Evfraxy in the US based on a settlement with Amgen , and has recently extended the partnership to Europe and Rest-of-World (RoW) markets. By Online Bureau ,